Vertex Prices Cystic Fibrosis Combo Treatment at $311,000-per-Year
Share
[aggregation-styles]
Reuters
Reuters
(Reuters) – Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis (CF) at $311,503 per year, after winning early U.S. approval on Monday.
Shares of the drugmaker, which also raised its 2019 sales forecast for CF products, were up 3% in after-hours trading.
The U.S. Food and Drug Administration approval, which comes five months ahead of the agency’s previously announced action date, greatly expands the percentage of cystic fibrosis patients that Vertex can treat.
Shares of the drugmaker, which also raised its 2019 sales forecast for CF products, were up 3% in after-hours trading.
The U.S. Food and Drug Administration approval, which comes five months ahead of the agency’s previously announced action date, greatly expands the percentage of cystic fibrosis patients that Vertex can treat.
RELATED TOPICS:
Categories
Latest
Videos
Crime /
13 mins ago
Fresno Police Arrest 13-Year-Old for Threatening a School Shooting
Business /
56 mins ago
Labor Costs Remain High for Small Businesses, but a Report Shows Wage Growth Is Slowing for Some
LA Rams /
1 hour ago
Rams Face Major Challenges After Key Injuries in Season-Opening Loss to Lions
Science /
1 hour ago
Partial Eclipse of Harvest Supermoon to Light Up the Sky on Sept. 17
Economy /
1 hour ago
Stock Market Today: Wall Street Holds Relatively Steady Following Weeks of Sharp Swings
Weather /
1 hour ago
